1-14 of 14
Stephanie Lheureux
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)

Open Access
Husam A. Alqaisi, David E. Cohn, Jing-Yi Chern, Linda R. Duska, Andrea Jewell, Bradley R. Corr, Ira Seth Winer, Eugenia Girda, Marta A. Crispens, Neesha C. Dhani, Ainhoa Madariaga, Robert C. Grant, Matthew Malaguti, Crystal Lee, Valerie Bowering, Horace Wong, Andrew Poothullil, Vanessa Speers, Lisa Wang, Philippe L. Bedard, John C. Brady, Andrew B. Nixon, Li Chen, Claire O’Connor, William Zamboni, Tawyna McKee, Jeffrey A. Moscow, Amit M. Oza, Stephanie Lheureux
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (6): 993–1001.
https://doi.org/10.1158/1078-0432.CCR-24-3128
Published: 17 March 2025
View articletitled, Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Open the PDF for Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) in another window
Includes: Supplementary data
Journal Articles

Genomic Landscape of ctDNA and Real-World Outcomes in Advanced Endometrial Cancer

Open Access
Pamela Soberanis Pina, Keelia Clemens, Adrian Bubie, Brooke Grant, Ginger Haynes, Nicole Zhang, Leylah Drusbosky, Stephanie Lheureux
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (24): 5657–5665.
https://doi.org/10.1158/1078-0432.CCR-24-2105
Published: 16 December 2024
View articletitled, Genomic Landscape of ctDNA and Real-World Outcomes in Advanced Endometrial Cancer
Open the PDF for Genomic Landscape of ctDNA and Real-World Outcomes in Advanced Endometrial Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A012: Genomic landscape of somatic alterations identified in endometrial cancer using liquid biopsy

Free
Leylah Drusbosky, Ginger Haynes, Brooke Grant, Pamela Sobernis, Stephanie Lheureux
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (5_Supplement): A012.
https://doi.org/10.1158/1557-3265.ENDO24-A012
Published: 01 March 2024
View articletitled, Abstract A012: Genomic landscape of somatic alterations identified in endometrial cancer using liquid biopsy
Journal Articles

Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib

Open Access
Ezra Rosen, Timothy A. Yap, Elizabeth K. Lee, Martin Højgaard, Niharika B. Mettu, Stephanie Lheureux, Benedito A. Carneiro, Ruth Plummer, Adrian J. Fretland, Danielle Ulanet, Yi Xu, Robin McDougall, Maria Koehler, Elisa Fontana
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 687–694.
https://doi.org/10.1158/1078-0432.CCR-23-2080
Published: 16 February 2024
View articletitled, Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib
Open the PDF for Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib in another window
Includes: Supplementary data
Journal Articles

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Open Access
Stephanie Lheureux, Stephenie D. Prokopec, Leslie E. Oldfield, Eduardo Gonzalez-Ochoa, Jeffrey P. Bruce, Derek Wong, Arnavaz Danesh, Dax Torti, Jonathan Torchia, Alexander Fortuna, Sharanjit Singh, Matthew Irving, Kayla Marsh, Bernard Lam, Vanessa Speers, Aleksandra Yosifova, Ana Oaknin, Ainhoa Madariaga, Neesha C. Dhani, Valerie Bowering, Amit M. Oza, Trevor J. Pugh
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18): 3706–3716.
https://doi.org/10.1158/1078-0432.CCR-23-0797
Published: 15 September 2023
View articletitled, Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Open the PDF for Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression in another window
Includes: Supplementary data
Journal Articles

Multi-omics Uncovering Different Faces of Clear Cell Ovarian Cancer

Available to Purchase
Stephanie Lheureux
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (22): 4838–4839.
https://doi.org/10.1158/1078-0432.CCR-22-2365
Published: 14 November 2022
View articletitled, Multi-omics Uncovering Different Faces of Clear Cell Ovarian Cancer
Open the PDF for Multi-omics Uncovering Different Faces of Clear Cell Ovarian Cancer in another window
Journal Articles

EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression

Available to Purchase
Stephanie Lheureux, Ana Oaknin, Swati Garg, Jeffrey P. Bruce, Ainhoa Madariaga, Neesha C. Dhani, Valerie Bowering, Justin White, Sarah Accardi, Qian Tan, Marsela Braunstein, Katherine Karakasis, Iulia Cirlan, Stephanie Pedersen, Tiantiam Li, Lorena Fariñas-Madrid, Yeh Chen Lee, Zhihui (Amy) Liu, Trevor J. Pugh, Amit M. Oza
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (16): 4206–4215.
https://doi.org/10.1158/1078-0432.CCR-19-4121
Published: 14 August 2020
View articletitled, EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
Open the PDF for EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)

Available to Purchase
Neesha C. Dhani, Hal W. Hirte, Lisa Wang, Julia V. Burnier, Angela Jain, Marcus O. Butler, Stephen Welch, Gini F. Fleming, Jean Hurteau, Koji Matsuo, Daniela Matei, Waldo Jimenez, Carolyn Johnston, Mihaela Cristea, Katia Tonkin, Prafull Ghatage, Stephanie Lheureux, Anjali Mehta, Judy Quintos, Qian Tan, Suzanne Kamel-Reid, Olga Ludkovski, Ming-Sound Tsao, John J. Wright, Amit M. Oza
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11): 2477–2486.
https://doi.org/10.1158/1078-0432.CCR-19-2576
Published: 01 June 2020
View articletitled, Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)
Open the PDF for Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86) in another window
Includes: Supplementary data
Journal Articles

DNA Methylation as a Robust Classifier of Epithelial Ovarian Cancer

Free
Charles A. Ishak, Stephanie Lheureux, Daniel D. De Carvalho
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (19): 5729–5731.
https://doi.org/10.1158/1078-0432.CCR-19-1797
Published: 01 October 2019
View articletitled, DNA Methylation as a Robust Classifier of Epithelial Ovarian Cancer
Open the PDF for DNA Methylation as a Robust Classifier of Epithelial Ovarian Cancer in another window
Journal Articles

A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium

Free
Stephanie Lheureux, Anna Tinker, Blaise Clarke, Prafull Ghatage, Stephen Welch, Johanne I. Weberpals, Neesha C. Dhani, Marcus O. Butler, Katia Tonkin, Qian Tan, David S.P. Tan, Kelly Brooks, Janelle Ramsahai, Lisa Wang, Nhu-An Pham, Patricia A. Shaw, Ming S. Tsao, Swati Garg, Tracey Stockley, Amit M. Oza
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (24): 6168–6174.
https://doi.org/10.1158/1078-0432.CCR-18-1244
Published: 13 December 2018
View articletitled, A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium
Open the PDF for A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium in another window
Includes: Supplementary data
Journal Articles

Biomarker Discovery from We to Me: Is Learning from Each Patient a New Approach?

Free
Stephanie Lheureux
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (14): 3233–3235.
https://doi.org/10.1158/1078-0432.CCR-18-0380
Published: 15 July 2018
View articletitled, Biomarker Discovery from We to Me: Is Learning from Each Patient a New Approach?
Open the PDF for Biomarker Discovery from We to Me: Is Learning from Each Patient a New Approach? in another window
Journal Articles

Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization

Free
Stephanie Lheureux, Zhongwu Lai, Brian A. Dougherty, Sarah Runswick, Darren R. Hodgson, Kirsten M. Timms, Jerry S. Lanchbury, Stan Kaye, Charlie Gourley, David Bowtell, Elise C. Kohn, Claire Scott, Ursula Matulonis, Tony Panzarella, Katherine Karakasis, Julia V. Burnier, C. Blake Gilks, Mark J. O'Connor, Jane D. Robertson, Jonathan Ledermann, J. Carl Barrett, Tony W. Ho, Amit M. Oza
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4086–4094.
https://doi.org/10.1158/1078-0432.CCR-16-2615
Published: 01 August 2017
View articletitled, Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization
Open the PDF for Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization in another window
Includes: Supplementary data
Journal Articles

Abstract PR16: Computational modeling of serous ovarian carcinoma dynamics: Implications for screening and therapy.

Free
Shengqing Gu, Stephanie Lheureux, Azin Sayad, Liat Hogen Ben-David, Iryna Vyarvelska, Paulina Cybulska, Marcus Bernardini, Barry Rosen, Amit Oza, Benjamin G. Neel
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2_Supplement): PR16.
https://doi.org/10.1158/1557-3265.OVCA15-PR16
Published: 15 January 2016
View articletitled, Abstract PR16: Computational modeling of serous ovarian carcinoma dynamics: Implications for screening and therapy.
Journal Articles

Abstract A35: Elucidating mechanisms involved in long-term response to platinum-based chemotherapy in high-grade serous ovarian cancer.

Free
Stephanie Lheureux, Cindy Yang, Patricia Shaw, Blaise Clarke, Julissa Tsao, Katherine Karakasis, Marcus Butler, Noor Salman, Mark Dowar, Jing Xu, Laurent Poulain, Pamela S. Ohashi, Trevor Pugh, Amit Oza
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2_Supplement): A35.
https://doi.org/10.1158/1557-3265.OVCA15-A35
Published: 15 January 2016
View articletitled, Abstract A35: Elucidating mechanisms involved in long-term response to platinum-based chemotherapy in high-grade serous ovarian cancer.